Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial

Pratley et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69df12429b582f29b9591706 — DOI: https://doi.org/10.1016/s2666-7568(23)00032-6

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase <scp>III</scp> studies· 2020 · 17 citations
2. Kidney Function and Fracture Risk: The Atherosclerosis Risk in Communities (ARIC) Study· 2015 · 65 citations
3. Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes· 2014 · 231 citations
4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes· 2015 · 11,907 citations
5. Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly· 2002 · 2,276 citations